TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24076296

Group type: EXPERIMENTAL
Intervention: Sympathetic denervation assessed using (11)C‐HED PET
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Absence of all 4 risk factors (PET sympathetic denervation, left ventricular end‐diastolic volume index, creatinine, and no angiotensin inhibition)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Presence of ≥2 risk factors
Number of subjects: 204
Study: 22705951

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided ilioinguinal and iliohypogastric nerve block with 20 mL bupivacaine 0.5%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo block with 20 mL saline
Number of subjects: 60
Study: 20038957

Group type: EXPERIMENTAL
Intervention: Docetaxel and thalidomide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Docetaxel alone
Number of subjects: 0
Study: 17563148

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control (smoking cessation plus weight control without exercise)
Number of subjects: 146
Study: 16282298

Group type: EXPERIMENTAL
Intervention: Ivermectin (400 microg/kg)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC) (6 mg/kg)
Number of subjects: 46
Study: 12011121

Group type: EXPERIMENTAL
Intervention: Aza C (75 mg/m² subcutaneous for 7 days every 4 weeks)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Aza C
Number of subjects: 191
Study: 10745332

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin G (IVIG) 1 g/kg on three consecutive days
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 7874928

Group type: EXPERIMENTAL
Intervention: Metered-dose inhaler (MDI) - 400 micrograms of albuterol
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Rotahaler - 400 micrograms of albuterol
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Diskhaler - 400 micrograms of albuterol
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: MDI in asthmatic subjects
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Diskhaler in asthmatic subjects
Number of subjects: 19

Group type: COMPARATOR
Intervention: MDI and Diskhaler
Number of subjects: 19
Study: 2211570

Group type: EXPERIMENTAL
Intervention: Buspirone (mean dose 41-54 mg/day from Week 2 to end of study)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Buspirone (for melancholic patients)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 347099

Group type: COMPARATOR
Intervention: Dexamethasone for 3 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Aerosolized gentamicin for 10 days
Number of subjects: 60
Study: 30831541

Group type: EXPERIMENTAL
Intervention: 10 mg melatonin (2 capsules of 5 mg each) once a day 1 hour before bedtime for 12 weeks
Number of subjects: 58
Study: 27864672

Group type: EXPERIMENTAL
Intervention: Rhinolight® intranasal phototherapy (combination of UV‐B, UV‐A, and high‐intensity visible light)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo group (low‐intensity visible white light intranasal phototherapy)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Rhinolight® intranasal phototherapy
Number of subjects: 34
Study: 26582137

Group type: EXPERIMENTAL
Intervention: Food advertisement
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (toy advertisement)
Number of subjects: 100
Study: 24779680

Group type: EXPERIMENTAL
Intervention: Azithromycin 250 mg daily
Number of subjects: 1113
Study: 23083020

Group type: EXPERIMENTAL
Intervention: Quetiapine 400 mg/day
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Quetiapine 800 mg/day
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 220
Study: 19930006

Group type: EXPERIMENTAL
Intervention: liraglutide 1.2 mg/metformin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: liraglutide 1.8 mg/metformin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: liraglutide (monotherapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: glimepiride/metformin
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 17347011

Group type: EXPERIMENTAL
Intervention: GH 0.1IU/kg/day [0.033mg/kg/day]
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GH 0.2IU/kg/day [0.067mg/kg/day]
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 16426800

Group type: EXPERIMENTAL
Intervention: Twice weekly functional-skills training
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Combination of resistance and functional-skills training
Number of subjects: 224

Group type: COMPARATOR
Intervention: Resistance training
Number of subjects: 224

Group type: COMPARATOR
Intervention: Control program
Number of subjects: 224
Study: 12044130

Group type: EXPERIMENTAL
Intervention: Alternative medicine therapies (specifics not provided)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo effect of unconventional medicine
Number of subjects: 0
Study: 9469978

Group type: EXPERIMENTAL
Intervention: Ad lib, low fat, high carbohydrate diet
Number of subjects: 43

Group type: COMPARATOR
Intervention: Fixed energy diet (< 8 MJ/day)
Number of subjects: 43
Study: 7892882

Group type: EXPERIMENTAL
Intervention: Hormonal replacement therapy
Number of subjects: 118

Group type: COMPARATOR
Intervention: Dietary calcium augmentation
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 2576217

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.1 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.2 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.3 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.4 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 795434

Group type: EXPERIMENTAL
Intervention: Diflucortolone valerate (Nerisona) in cream, ointment, and fatty ointment
Number of subjects: 1923

Group type: EXPERIMENTAL
Intervention: Diflucortolone valerate (Nerisona) ointment
Number of subjects: 1923

Group type: COMPARATOR
Intervention: Commercial preparations (beta‐methasone‐17‐valerate, fluocinonide, fluocinolone acetonide, flumetasone pivalate, desoximetasone)
Number of subjects: 1923
Study: 31394404

Group type: EXPERIMENTAL
Intervention: Observational studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cohort studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Case-control studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phase 4 observational studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Uncontrolled phase 1 studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient or disease registries
Number of subjects: 0
Study: 28333531

Group type: EXPERIMENTAL
Intervention: Healthy Living Triple P intervention (2 group sessions of 2 hours each)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 107
Study: 25368202

Group type: EXPERIMENTAL
Intervention: Increase in resting heart rate (HR) from preceding visit
Number of subjects: 7599

Group type: EXPERIMENTAL
Intervention: Lowering of resting heart rate (HR)
Number of subjects: 7599

Group type: EXPERIMENTAL
Intervention: Time-updated resting HR at each visit
Number of subjects: 7599
Study: 23549824

Group type: EXPERIMENTAL
Intervention: Remifentanil at effect-site concentration of 4 ng/mL (group R4)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Remifentanil at effect-site concentration of 2 ng/mL (group R2)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Remifentanil at effect-site concentration of 6 ng/mL (group R6)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Comparison among groups R2, R4, and R6
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Group R4
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Group R2
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Group R6
Number of subjects: 69
Study: 21749461

Group type: EXPERIMENTAL
Intervention: Multifaceted environmental exposure-reducing intervention
Number of subjects: 476

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 476
Study: 19414206

Group type: EXPERIMENTAL
Intervention: 5.6 mmol/l cutoff for impaired fasting glucose
Number of subjects: 5794

Group type: COMPARATOR
Intervention: 6.1 mmol/l cutoff for impaired fasting glucose
Number of subjects: 5794

Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance and fasting glucose
Number of subjects: 5794
Study: 16673249

Group type: EXPERIMENTAL
Intervention: Neoadjuvant TAC chemotherapy
Number of subjects: 70
Study: 15220788

Group type: EXPERIMENTAL
Intervention: 12 ml/h ropivacaine, 0.1% (group R)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 12 ml/h saline (group N)
Number of subjects: 30
Study: 12941031

Group type: EXPERIMENTAL
Intervention: Oral heparin/SNAC (90 000 U heparin)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Oral heparin/SNAC (60 000 U heparin)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Subcutaneous UFH (5000 U)
Number of subjects: 123
Study: 10438403

Group type: EXPERIMENTAL
Intervention: Growth hormone-releasing factor (GRF) 500 microg twice daily
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study: 7760609

Group type: EXPERIMENTAL
Intervention: Interferon-alpha n1 (IFN-alpha)
Number of subjects: 587

Group type: COMPARATOR
Intervention: Chemotherapy with busulphan or hydroxyurea (no IFN-alpha)
Number of subjects: 587
Study: 2138703

Group type: EXPERIMENTAL
Intervention: hANP infusion (0.3 micrograms/min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 8
Study: 7438382

Group type: EXPERIMENTAL
Intervention: Sulfinpyrazone (200 mg four times a day)
Number of subjects: 1558

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1558
Study: 29211236

Group type: EXPERIMENTAL
Intervention: Sacred music with vocals (Group 2)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Instrumental sacred music (Group 3)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 69
Study: 26288467

Group type: EXPERIMENTAL
Intervention: 2 g single supervised dose of azithromycin
Number of subjects: 292

Group type: COMPARATOR
Intervention: 500 mg azithromycin once daily for 5 days (conventional dose)
Number of subjects: 292
Study: 22753403

Group type: EXPERIMENTAL
Intervention: Joint space narrowing (JSN)
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Erosions
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Damage in the wrist
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Erosions in the wrist
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Erosions in the wrist (independently associated)
Number of subjects: 508
Study: 22269194

Group type: EXPERIMENTAL
Intervention: Ribbond ribbon + Composite
Number of subjects: 30

Group type: COMPARATOR
Intervention: Stainless steel wire + Composite
Number of subjects: 30
Study: 19178120

Group type: EXPERIMENTAL
Intervention: Randomized controlled trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observational data
Number of subjects: 0
Study: 16979581

Group type: EXPERIMENTAL
Intervention: Group-based cognitive therapy (CT)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Psychoeducational support groups
Number of subjects: 210

Group type: COMPARATOR
Intervention: Intensive symptom monitoring
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Group-based cognitive therapy (CT) and Psychoeducational support groups
Number of subjects: 210
Study: 14984447

Group type: EXPERIMENTAL
Intervention: Glucometer test strips provided free of charge (NC)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (C) had to purchase strips
Number of subjects: 62
Study: 11576817

Group type: EXPERIMENTAL
Intervention: Standard error as the vertical axis in funnel plots
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Precision or inverse of variance as the vertical axis in funnel plots
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Sample size or log sample size as the vertical axis in funnel plots
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Odds ratios or risk ratios on the horizontal axis
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Risk differences on the horizontal axis
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Funnel plots of meta-analyses using standard error as the measure of study size
Number of subjects: 78
Study: 9324340

Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation
Number of subjects: 62

Group type: COMPARATOR
Intervention: Intensive chemotherapy
Number of subjects: 62
Study: 8182401

Group type: EXPERIMENTAL
Intervention: Acupuncture and placebo tablets
Number of subjects: 85

Group type: COMPARATOR
Intervention: Metoprolol 100 mg daily
Number of subjects: 85
Study: 29554406

Group type: EXPERIMENTAL
Intervention: Pharyngeal pack placement under videolaryngoscopic guidance (video guidance group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Pharyngeal pack placement blindly (blind insertion group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No pharyngeal pack (control group)
Number of subjects: 80
Study: 27529693

Group type: EXPERIMENTAL
Intervention: Play-based intervention (six clinic play-sessions, weekly home-modules, one-month home follow-up)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (waitlist for 10 weeks)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Combined data from both groups
Number of subjects: 29
Study: 24431325

Group type: EXPERIMENTAL
Intervention: Calcium-sensing receptor-activating amino acids (CaSR-AAAs) L-tryptophan, L-phenylalanine, and L-histidine
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Dibasic amino acids (DAAs) L-arginine and L-lysine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control diet (methylcellulose capsules)
Number of subjects: 14
Study: 22622073

Group type: EXPERIMENTAL
Intervention: Surgical treatment (surgical exclusion of the internal carotid artery stump combined with endarterectomy of the external carotid artery)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Best medical treatment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 40
Study: 20524190

Group type: EXPERIMENTAL
Intervention: Bioactive glass (BG) - S53P4
Number of subjects: 21

Group type: COMPARATOR
Intervention: Autogenous bone (AB)
Number of subjects: 21
Study: 18024166

Group type: EXPERIMENTAL
Intervention: Bi-level positive pressure ventilation (S/T mode)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Adaptive servo ventilation (AutoSetCS)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control investigations after 6 weeks
Number of subjects: 37
Study: 16876399

Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 942
Study: 12826837

Group type: EXPERIMENTAL
Intervention: Colforsin daropate (0.75 microg. kg‐1 x min‐1 intravenously)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 46
Study: 11022066

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Number of subjects: 109

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 109
Study: 8781005

Group type: EXPERIMENTAL
Intervention: Multimodal culturally specific intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-help intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive intervention for Baptists
Number of subjects: 0
Study: 1452560

Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 22
Study: 3880995

Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 376

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 376
Study: 31707827

Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study: 29950826

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) 36/9.6 µg
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) 36/7.2 µg
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) 18/9.6 µg
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) 9/9.6 µg
Number of subjects: 185

Group type: COMPARATOR
Intervention: Glycopyrrolate (GP) MDI 36 µg
Number of subjects: 185

Group type: COMPARATOR
Intervention: Formoterol fumarate (FF) MDI 9.6 µg
Number of subjects: 185
Study: 26248047

Group type: EXPERIMENTAL
Intervention: Quinidine (600 mg PO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naloxegol (25 mg PO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphine (5 mg/70 kg IV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quinidine and naloxegol combination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25242045

Group type: EXPERIMENTAL
Intervention: Panobinostat, bortezomib, and dexamethasone
Number of subjects: 768

Group type: COMPARATOR
Intervention: Placebo, bortezomib, and dexamethasone
Number of subjects: 768
Study: 22796472

Group type: EXPERIMENTAL
Intervention: aCRT
Number of subjects: 522

Group type: COMPARATOR
Intervention: Echo
Number of subjects: 522
Study: 19606937

Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan combination therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 0
Study: 17626056

Group type: COMPARATOR
Intervention: Combined hormone therapy (conjugated equine oestrogens plus medroxyprogesterone acetate 2.5/5.0 mg orally daily)
Number of subjects: 5692

Group type: COMPARATOR
Intervention: Combined hormone therapy
Number of subjects: 5692
Study: 16307967

Group type: EXPERIMENTAL
Intervention: 600 microg oral misoprostol (single-dose)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 1200 microg oral misoprostol (repeated-dose)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 300
Study: 11927189

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9795070

Group type: EXPERIMENTAL
Intervention: New levodopa/benserazide dual-release formulation (DRF)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional slow-release formulation (SRF)
Number of subjects: 18
Study: 7544670

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 23

Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 23
Study: 2496310

Group type: EXPERIMENTAL
Intervention: Buserelin with HMG
Number of subjects: 44

Group type: COMPARATOR
Intervention: Clomiphene citrate with HMG
Number of subjects: 44
Study: 4898

Group type: EXPERIMENTAL
Intervention: alpha‐methyldopa
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: timolol
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 30830180

Group type: EXPERIMENTAL
Intervention: Testosterone treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 27830967

Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitors (TKIs)
Number of subjects: 1710

Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 1710
Study: 25915168

Group type: EXPERIMENTAL
Intervention: Aprepitant (375 mg once daily for 2 weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 24210844

Group type: EXPERIMENTAL
Intervention: Non-invasive autoinflation device
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 31
Study: 21407132

Group type: EXPERIMENTAL
Intervention: Nitrate supplementation (NaNO(3) 10 mg·kg(‐1) of body mass)
Number of subjects: 11
Study: 19585385

Group type: EXPERIMENTAL
Intervention: Intraprostatic injections with mepivacaine epinephrine
Number of subjects: 85

Group type: COMPARATOR
Intervention: No intraprostatic injections
Number of subjects: 85
Study: 17760598

Group type: EXPERIMENTAL
Intervention: 7% lidocaine and 7% tetracaine (LT) peel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo or 1:1 eutectic mixture of local anesthetics (EMLA) cream
Number of subjects: 0
Study: 15220241

Group type: EXPERIMENTAL
Intervention: Pioglitazone (15 to 45 mg, titrated based on tolerability)
Number of subjects: 5238

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5238
Study: 11176310

Group type: EXPERIMENTAL
Intervention: Low-field extremity MR system (E-MRI: 0.2 T) with T2-weighted turbo SE (TSE) sequences
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Low-field extremity MR system (E-MRI: 0.2 T) with MTC sequences
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Low-field extremity MR system (E-MRI: 0.2 T) with T1-weighted SE sequences
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Low-field extremity MR system (E-MRI: 0.2 T) with T2-weighted TSE sequences
Number of subjects: 22
Study: 9702847

Group type: EXPERIMENTAL
Intervention: Sustained-release tablet of naproxen (500 mg once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional tablet of naproxen (250 mg twice daily)
Number of subjects: 0
Study: 7971867

Group type: EXPERIMENTAL
Intervention: 15-session, skills-based HIV prevention curriculum implemented by trained teachers
Number of subjects: 2844

Group type: COMPARATOR
Intervention: Comparison condition (no intervention)
Number of subjects: 2844
Study: 2478790

Group type: EXPERIMENTAL
Intervention: 5 mg UD-CG 115 BS (pimobendan)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 mg UD-CG 115 BS (pimobendan)
Number of subjects: 12
Study: 335788

Group type: EXPERIMENTAL
Intervention: Pizotifen (4-10 mg daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29118014

Group type: EXPERIMENTAL
Intervention: Exercise training (12-week supervised program)
Number of subjects: 22
Study: 27137926

Group type: EXPERIMENTAL
Intervention: Hydrogel coils
Number of subjects: 484

Group type: COMPARATOR
Intervention: Bare platinum coils
Number of subjects: 484
Study: 25350037

Group type: EXPERIMENTAL
Intervention: Aerobic and strength conditioning exercise
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 63
Study: 22153550

Group type: EXPERIMENTAL
Intervention: HeartMate II continuous-flow LVAD
Number of subjects: 126

Group type: COMPARATOR
Intervention: HeartMate XVE pulsatile-flow LVAD
Number of subjects: 126